CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC

被引：4
|
作者：
Pacheco, Jose M. [1 ]
Schenk, Erin L. [1 ]
机构：
[1] Univ Colorado, Dept Internal Med, Div Med Oncol, Ctr Canc, Anschutz Med Campus,1665 Aurora Court, Aurora, CO 80045 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
基金：
美国国家卫生研究院;
关键词：
CELL LUNG-CANCER; PATHWAY;
D O I：
10.1016/j.jtho.2021.01.1623
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 511
页数：3
相关论文
共 50 条
  • [11] Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
    Kim, Youjin
    Lee, Boram
    Shim, Joon Ho
    Lee, Se-Hoon
    Park, Woong-Yang
    Choi, Yoon-La
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (02) : 193 - 202
  • [12] CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
    Harvey, Jerry B.
    Phan, Luan H.
    Villarreal, Oscar E.
    Bowser, Jessica L.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [13] Roles of the Adenosine Receptor and CD73 in the Regulatory Effect of γδ T Cells
    Liang, Dongchun
    Zuo, Aijun
    Shao, Hui
    Chen, Mingjiazi
    Kaplan, Henry J.
    Sun, Deming
    PLOS ONE, 2014, 9 (09):
  • [14] CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells
    Katsuta, Eriko
    Tanaka, Shinji
    Mogushi, Kaoru
    Shimada, Shu
    Akiyama, Yoshimitsu
    Aihara, Arihiro
    Matsumura, Satoshi
    Mitsunori, Yusuke
    Ban, Daisuke
    Ochiai, Takanori
    Kudo, Atsushi
    Fukamachi, Hiroshi
    Tanaka, Hiroshi
    Nakayama, Koh
    Arii, Shigeki
    Tanabe, Minoru
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (02) : 657 - 669
  • [15] Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
    Yang, Jiayin
    Liao, Xiaohong
    Yu, Jerry
    Zhou, Ping
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (19) : 2260 - 2271
  • [16] CD73: A therapeutic target for pancreatic neuroendocrine tumor stem cells
    Katsuta, Eriko
    Tanaka, Shinji
    Mogushi, Kaoru
    Shimada, Shu
    Akiyama, Yoshimitsu
    Aihara, Arihiro
    Matsumura, Satoshi
    Mitsunori, Yusuke
    Ban, Daisuke
    Ochiai, Takanori
    Kudo, Atsushi
    Fulcamachi, Hiroshi
    Tanaka, Hiroshi
    Nakayama, Koh
    Arii, Shigeki
    Tanabe, Minoru
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S5 - S5
  • [17] The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
    Oh, Seung Yeon
    Park, Sewon
    Lee, Seoyoung
    Lee, Eun Ji
    Kim, Tae Ho
    Choi, Su-Jin
    Park, So Young
    Kim, Jae Hwan
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    Hong, Min Hee
    Yun, Mi Ran
    CELL REPORTS MEDICINE, 2025, 6 (02)
  • [18] Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
    de Leve, Simone
    Wirsdoerfer, Florian
    Jendrossek, Verena
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [19] The role of ectonucleotidases CD39 and CD73 and adenosine signaling in solid organ transplantation
    Roberts, Veena
    Stagg, John
    Dwyer, Karen M.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [20] Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
    Tu, Eric
    McGlinchey, Kelly
    Wang, Jixin
    Martin, Philip
    Ching, Steven L. K.
    Floc'h, Nicolas
    Kurasawa, James
    Starrett, Jacqueline H.
    Lazdun, Yelena
    Wetzel, Leslie
    Nuttall, Barrett
    Ng, Felicia S. L.
    Coffman, Karen T.
    Smith, Paul D.
    Politi, Katerina
    Cooper, Zachary A.
    Streicher, Katie
    JCI INSIGHT, 2022, 7 (03)
12345